ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
1 story in the last 7 days
The latest cell therapy news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks cell therapy across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.

Cambridge biotech bit.bio raised $25 million in Series D funding on Wednesday, ten months after its Series C. Backed by M&G Investments and Dr Jonathan Milner, the company plans to expand cell types and customer base rather than build new infrastructure.
Summaries by ByteBrief